UMR1027, INSERM-UNIVERSITY PAUL SABATIER Toulouse III joint research unit.
Director : Sandrine Andrieu
The epidemiological approach is common to all of the teams. It is based around the implementation of specific tools, and notably numerous studies, both cross-sectional and longitudinal. Another feature of our unit is that it possesses three disease registers: the Haute-Garonne coronary disease register, the Tarn cancer register, and the Haute-Garonne register of childhood disabilities. This original system enables the exchange of knowledge and data.
The unit is composed of 6 teams
Team 1 : Aging and Alzheimer disease: from observation to intervention.
Team 2 : SPHERE - Study of Perinatal, paediatric and adolescent Health: Epidemiology, surveillance Reports and Evaluation of clinical interventions and services
Team 3 : The epidemiology of atherosclerosis and cardiovascular diseases: risk factors and management in the population.
Team 4 : Genomics, biotherapy and public health:interdisciplinary approach.
Team 5 : Cancer and chronic diseases: social inequalities in health, access to primary and secondary care.
Team emergent : Pharmacoepidemiology, assessment of drug utilisation and drug safety.
Scientific project
Research into the determining factors, management options and consequences of chronic diseases and disabilities, within a constantly changing environment (financial constraints, health security, increasing inequalities). The study takes a multidisciplinary approach: epidemiology, clinical studies, sociology, psychology, health economy, technology and the law. The individual is considered from an individual, biological, physical and psychological perspective and within his/her family and social environment.
Patents / Partnerships
International cooperation
Cardiovascular diseases international research network (Regicor Barcelona, Queen's University of Belfast); European Alzheimer's Disease Consortium (EADC); European Cerebral Palsy Surveillance Network (SCPE and SPARCLE); European haematopoietic stem cell transplants donor registry programme and the role of genomics, sociology, economy, law and ethics (MADO and POSEIDON)
in the ethical aspects of reprogramming the immune system for the establishment of tolerance (RISET), and in the study of health inequalities (EUROTHINE); Joint international project (ACI) on genetics and public health; coordination of the 6th PCRDT (Population Biobank.
10 Principal Centre Publications
Team 1 > Nourhashemi F, Andrieu S, Gillette-Guyonnet S, Giraudeau B, Cantet C, Coley N, Vellas B; PLASA Group. Effectiveness of a specific care plan in patients with Alzheimer's disease: cluster randomised trial (PLASA study). BMJ. 2010.340:c2466. doi: 10.1136/bmj.c2466.

> Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G; Europen Task Force Group. Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol. 2008.7(5):436-50.

Team 2 > Delobel-Ayoub M, Arnaud C, White-Koning M, Casper C, Pierrat V, Garel M, Burguet A, Roze JC, Matis J, Picaud JC, Kaminski M, Larroque B; EPIPAGE Study Groupand al. Behavioral problems and cognitive performance at five years of age after very preterm birth : The EPIPAGE Study, Pediatrics. 2009.123(6):1485-92.

> Arnaud C, White-Koning M, Michelsen SI, Parkes J, Parkinson K, Thyen U, Beckung E, Dickinson HO, Fauconnier J, Marcelli M, McManus V, Colver A. Parent-reported quality of life of children with cerebral palsy in Europe. Pediatrics. 2008.121(1):54-64.

Team 3 > Ruidavets JB, Ducimetière P, Evans A, Montaye M, Haas B, Bingham A, Yarnell J, Amouyel P, Arveiler D, Kee F, Bongard V, Ferrières J. Patterns of alcohol consumption and ischaemic heart disease in culturally-divergent countries: The prospective epidemiological study of myocardial infarction (PRIME). BMJ. 2010. 341:c6077 doi: 10.1136/bmj.c6077

> Cournot M, Taraszkiewicz D, Cambou JP, Galinier M, Boccalon H, Hanaire-Broutin H, Chamontin B, Carrié D, Ferrières J. Additional prognostic value of physical examination, exercise testing, and arterial ultrasonography for coronary risk assessment in primary prevention. Am Heart J. 2009.158 (5):845-51.

Team 4 > Kauffmann F., Cambon-Thomsen A. Tracing biological collections: between books and clinical trials. JAMA. 2008.299(19):2316-8.

> Boyer J.F., Gourraud PA, Cantagrel A, Davignon JL, Constantin A.Traditional cardiovascular risk factors in rheumatoid arthritis: A meta-analysis. Joint Bone Spine. 2011. 78(2):179-83.

Team 5 > Kelly-Irving M., Mulot S, Inamo J, Ruidavets JB, Atallah A , Lang T. Improving stroke prevention in the French West Indies: limits to lay knowledge of risk factors. Stroke. 2010. 41 (11):2637-44. 

> Delpierre C, Lauwers-Cances V, Datta GD, Berkman L, Lang T. Impact of social position on the effect of cardiovascular risk factors on self-rated health. Am J Public Health. 2009. 99(7):1278-84.

Team emergent > Weill A, Païta M., Tuppin P, Fagot JP, Neumann A, Simon D, Ricordeau P, Montastruc JL, Allemand H. Benfluorex and valvular heart disease : a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf. 2010.19(12):1256-62. doi: 10.1002/pds.2044.

> Brefel-Courbon C, Grolleau S, Thalamas C, Bourrel R, Allaria-Lapierre V, Loï R, Micallef-Roll J, Lapeyre-Mestre M. Comparison of chronic analgesic drugs prevalence in Parkinson's disease, other chronic diseases and the general population. Pain. 2009.141:14-8

Lien vers la version française du site